Lymphoblastic Leukemia With P2RY8::CRLF2 Rearrangement and High Hyperdiploidy.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Improved survival rate in pediatric acute lymphoblastic leukemia (ALL) warrants efforts to optimize treatment intensity in good-prognostic groups such as those with high hyperdiploidy (HHD). Cytokine receptor-like factor 2 (CRLF2) alteration is frequently detected in Philadelphia chromosome-like ALL, which has a high relapse ratio and no consensus treatment strategy. P2RY8::CRLF2-positive childhood ALL is frequently associated with disease recurrence. To the best of our knowledge, there have been no previous case reports of an ALL patient with P2RY8::CRLF2 fusion gene, CRLF2 high expression, and HHD that have included a detailed description of the clinical course. Here we report the case of a 3.3-year-old Sri Lankan boy diagnosed with B-cell precursor (BCP) ALL with P2RY8::CRLF2, CRLF2 hyperexpression, and HHD. The patient's rapid minimal residual disease (MRD) clearance and HHD karyotype supported classification as standard-risk, per Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL2000) criteria. However, the contribution of CRLF2 overexpression to long-term risk remains uncertain. At 54 months since diagnosis, he remains in good health following his initial complete response.